Cause of death in men diagnosed with prostate carcinoma.
about
Prevalence of pesticide exposure in young males (</= 50 years) with adenocarcinoma of the prostateThe role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UKInhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols.Association of African-American ethnic background with survival in men with metastatic prostate cancer.The cellular and molecular basis of prostate cancer.Prostate cancer treatment and survival: evidence for men with prevalent comorbid conditions.Pretreatment predictors of death from other causes in men with prostate cancer.S100A4 accelerates tumorigenesis and invasion of human prostate cancer through the transcriptional regulation of matrix metalloproteinase 9Metabolic complications and increased cardiovascular risks as a result of androgen deprivation therapy in men with prostate cancer.What do prostate cancer patients die of?The current practice of screening, prevention, and treatment of androgen-deprivation-therapy induced osteoporosis in patients with prostate cancer.The impact of age and comorbidity on survival outcomes and treatment patterns in prostate cancer.Long-term outcome among men with conservatively treated localised prostate cancer.Green tea catechins suppress the DNA synthesis marker MCM7 in the TRAMP model of prostate cancer.Differences in Hypercholesterolemia and Atherogenesis Induced by Common Androgen Deprivation Therapies in Male Mice.Assessment of causes of death in a prostate cancer screening trial.Tissue vaccines for cancer.Cause of Death in Korean Men with Prostate Cancer: an Analysis of Time Trends in a Nationwide Cohort.Metabolic sequelae associated with androgen deprivation therapy for prostate cancer.A novel DNA methylation score accurately predicts death from prostate cancer in men with low to intermediate clinical risk factors.Metformin in prostate cancer: two for the price of one.Cardiovascular Complications of Androgen Deprivation Therapy for Prostate Cancer.Evaluating long-term patient-centered outcomes following prostate cancer treatment: findings from the Michigan Prostate Cancer Survivor study.Assessing the impact of comorbid illnesses on death within 10 years in prostate cancer treatment candidates.Naftopidil, a selective alpha-1 adrenoceptor antagonist, inhibits growth of human prostate cancer cells by G1 cell cycle arrest.Prostate cancer treatment does not increase the risk of cardiovascular eventsAndrogen deprivation by flutamide modulates uPAR, MMP-9 expressions, lipid profile, and oxidative stress: amelioration by daidzein.Clinicopathological features of prostate cancer in Jamaican men.Erectile dysfunction is predictive of all-cause mortality in patients with prostate cancer treated with permanent interstitial brachytherapy.Cause-specific mortality following radical prostatectomy.High accuracy of Swedish death certificates in men participating in screening for prostate cancer: a comparative study of official death certificates with a cause of death committee using a standardized algorithm.The association of weight gain during adulthood with prostate cancer incidence and survival: a population-based cohort.Prostate carcinoma and green tea: (-)epigallocatechin-3-gallate inhibits inflammation-triggered MMP-2 activation and invasion in murine TRAMP model.Analysis of the lipid profile and atherogenic risk during androgen deprivation therapy in prostate cancer patients.Impact of metabolic disorders on prostate cancer growth: Androgen and insulin resistance perspectives.Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy.
P2860
Q24792282-7195645C-BE7D-4FE1-962C-F7B1A90DDACAQ28072710-42BE8DBA-C4E3-40D9-982E-6468EB7BE1F7Q30658549-7AE3918C-C9A9-449A-A584-0DC9D4E62F21Q31832022-B51182AE-6D95-4C01-A7BF-1626BA497CCBQ33610876-E22B6A7F-0C04-49EA-B922-88FEFB837415Q34031286-0BA47755-7D2F-438F-9013-B53B44AAD7C3Q34454050-406F6590-1152-47BF-85F9-69451F461D6EQ35075493-73138E43-56A6-497E-BBA2-FE9A82320538Q35433102-8562F6AF-3B6E-4A5A-8607-1558CA1953D5Q35584421-9712ED3A-E8C5-4594-8FF2-D8AF7A226165Q35954808-4F496354-5EBA-4988-B41E-E837426089B8Q36034209-87678817-7F7C-4774-9FE8-065D88E19E68Q36611890-5B90F1FD-09A0-400D-B338-690E6C968848Q36692363-F2BBF0F5-66AA-46A4-A790-9EFDAA574A60Q36714085-252AA9CE-5A66-4919-BC74-1C3C0236EEB2Q36970410-58D1FDBF-2652-49EB-ADD8-E2CFE2BC7B6AQ37123446-10B670D4-A0F3-4CCE-AEC1-D6C84FDE58CCQ37323456-5435BC59-F649-4079-8221-89AD62248E24Q37431937-2A89E209-093B-43EE-AA5F-D7952025C999Q37687723-A8DD823F-BA6A-44D1-A221-BA17870D3DA4Q37855307-80708F4A-1BAF-4A45-A567-D358A2C18D0DQ38707724-99525A1A-9F49-4FBB-8CD7-9C18492EA311Q39317893-50FBE331-4DC0-48CF-A203-D827513E99E4Q39715470-4BD2CC57-0C87-4933-A301-E7F6B26F697AQ40071688-2CAA8798-4A13-4527-8459-F723BD95CDE0Q41909293-21EF60F2-3053-4104-B9E3-6C513315C6E5Q42714392-70821B29-AEBA-46CE-8B89-B616E0D9921EQ44346656-0C89AB32-26E9-40E7-BC26-CE1716EB1A40Q44402409-2528FE8E-847A-48C8-B5A3-8BF964AE6CE4Q44466033-A1694E7A-08E8-48AA-A632-25A8723FB0C2Q44629190-A37A59D7-0264-443D-B077-63EB8D4EEBB6Q44759736-A84AF25E-39E4-444E-BDF8-6DDE19C15446Q45073483-1BEDE2E0-218F-4A6E-860C-7306093ADCAEQ46125397-0DA8D3FD-4B6E-4659-B692-88F0CE97DF14Q47129584-775E0075-DFFD-48F8-A9F8-B2D631EF80ECQ51499900-FD42816D-C0C7-4F45-8F22-FE36D92F5C29
P2860
Cause of death in men diagnosed with prostate carcinoma.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Cause of death in men diagnosed with prostate carcinoma.
@en
Cause of death in men diagnosed with prostate carcinoma.
@nl
type
label
Cause of death in men diagnosed with prostate carcinoma.
@en
Cause of death in men diagnosed with prostate carcinoma.
@nl
prefLabel
Cause of death in men diagnosed with prostate carcinoma.
@en
Cause of death in men diagnosed with prostate carcinoma.
@nl
P2093
P2860
P1433
P1476
Cause of death in men diagnosed with prostate carcinoma.
@en
P2093
Ragland KE
Satariano WA
Van Den Eeden SK
P2860
P304
P356
10.1002/(SICI)1097-0142(19980915)83:6<1180::AID-CNCR18>3.0.CO;2-1
P407
P577
1998-09-01T00:00:00Z